cell and gene therapy

Open For Business Dana Cipriano, Global Head of Analytical Services, cuts the ribbon to mark the opening of SK pharmteco’s state-of-the-art 20,000-square-foot CGMP testing facility at SK pharmteco’s King of Prussia campus. The facility is the future home of SK pharmteco’s Lentiviral Vector (LVV) Analytical Services, a comprehensive suite of analytical testing solutions specifically designed for LVV and cell therapy programs.

SK pharmteco Launches New Lentiviral Vector Analytical Services with Dedicated 20,000 sq. ft. Facility 

FOR IMMEDIATE RELEASE  SK pharmteco Launches New Lentiviral Vector Analytical Services with Dedicated 20,000 sq. ft. Facility  King of Prussia, PA (May 21, 2024)—SK pharmteco, a global contract development, manufacturing, and analytical testing organization serving the pharmaceutical and cell & gene therapy industry, today announced the upcoming launch of Lentiviral Vector (LVV) Analytical Services, a […]

SK pharmteco Launches New Lentiviral Vector Analytical Services with Dedicated 20,000 sq. ft. Facility  Read More »

SK pharmteco to Showcase Breakthroughs in Drug Manufacturing at ASGCT Meeting in Baltimore

FOR IMMEDIATE RELEASE SK pharmteco to Showcase Breakthroughs in Drug Manufacturing at ASGCT Meeting in Baltimore   RANCHO CORDOVA, Ca. (May 6, 2024) – SK pharmteco, a global contract development and manufacturing organization serving the pharmaceutical industry, will unveil advancements in gene and cell therapy manufacturing through eightresearch poster presentations at the upcoming annual meeting of

SK pharmteco to Showcase Breakthroughs in Drug Manufacturing at ASGCT Meeting in Baltimore Read More »

Comprehensive and Accelerated Testing Programs for Cell and Gene Therapies

SK pharmteco’s Cell and Gene Therapy Analytical Testing Services are readily available and positions our clients to successfully meet the challenges associated with commercializing cell and gene therapies.  We offer full testing programs that can be customized to specific products and modalities.  A complete package of platform assays meets the full spectrum of global regulatory

Comprehensive and Accelerated Testing Programs for Cell and Gene Therapies Read More »

Ferring Pharmaceuticals and SK pharmteco enter into commercial gene therapy manufacturing deal

Biopharmaceutical contract manufacturer SK pharmteco commits to production, testing, and release of Ferring’s U.S. approved Adstiladrin® (nadofaragene firadenovec-vncg) The deal assures diversity of supply to meet future long-term plans for expanded availability of the gene therapy Two additional state-of-the-art manufacturing facilities for Adstiladrin® are near completion in Finland and the U.S. Saint-Prex, Switzerland and King

Ferring Pharmaceuticals and SK pharmteco enter into commercial gene therapy manufacturing deal Read More »

Momentum in Cell & Gene Therapy Symposium

ART-TG and SK pharmteco are thrilled to invite you to the inaugural Momentum in Cell & Gene Therapy Symposium,register below!  Click here to register Download the program Join us for a journey through the latest advancements and innovations in Cell and Gene therapy. Featuring world-renowned speakers and key players in the fields of R&D, clinical research, or biotechnology, this immersive

Momentum in Cell & Gene Therapy Symposium Read More »

John Lee, Global Head of CGT Published in Cytotherapy – CGT Development: Selecting the Right CDMO

Cell and Gene Therapy Development: Selecting the Right Contract Development and Manufacturing Organization In recent years, the number of cell and gene therapy (CGT) clinical trials has boomed, and so has the need for contract development and manufacturing organizations (CDMOs).  For any size biotech company developing CGT products,  selecting the right CDMO is crucial for

John Lee, Global Head of CGT Published in Cytotherapy – CGT Development: Selecting the Right CDMO Read More »

Nitrosamines: An Overview

Nitrosamines are organic compounds found in the human diet and other environmental outlets. Being potent carcinogens that can cause tumors in nearly all organs, they have been classified as genotoxic impurities (GTIs). There are guidelines and rulings by various regulatory organizations, including the FDA, EPA, EMA, and the IARC (International Agency for Research on Cancer).

Nitrosamines: An Overview Read More »

From The Korea Economic Daily: SK pharmteco Launches New Viral Vector Platforms, Key for CGT

The Korean CDMO’s new viral vector platforms can significantly save the production time and cost of AAV and lentiviral vectors By Ji-Hyun Lee SK pharmteco Co., South Korean conglomerate SK Group’s contract development and manufacturing organization (CDMO), has recently introduced two new viral vector platforms that are expected to save the time and cost of

From The Korea Economic Daily: SK pharmteco Launches New Viral Vector Platforms, Key for CGT Read More »

Scroll to Top

Enter your details to access Marketing Materials